Table I.
Clinical characteristics and FBC parameters at presentation.
| Characteristic | All patients (n = 76) | Severe/critical (n = 20) | Mild (n = 56) | P * |
|---|---|---|---|---|
| Age, years, median (range) | 46 (19–71) | 58 (36–70) | 38 (19–71) | 0·0002 |
| Women, n (%) | 32 (42·1) | 6 (30·0) | 26 (46·4) | |
| Ethnicity, n (%) | ||||
| Chinese | 52 (68·4) | 17 (85) | 35 (62·5) | |
| Malay | 4 (5·3) | 2 (10) | 2 (3·6) | |
| Indian | 3 (3·9) | 1 (5) | 2 (3·6) | |
| Caucasian | 11 (14·5) | 0 (0) | 11 (19·6) | |
| Others | 6 (7·9) | 0 (0) | 6 (10·7) | |
| Major illness, n (%) | ||||
| Hypertension | 19 (25·0) | 8 (40) | 11 (19·6) | 0·070 |
| Ischaemic heart disase | 19 (25·0) | 8 (40) | 11 (19·6) | 0·070 |
| Dyslipidaemia | 2 (2·6) | 1 (5) | 1 (1·8) | 0·440 |
| Heart failure | 1 (1·7) | 1 (5) | 0 (0) | |
| Previous strokes | 1 (1·7) | 1 (5) | 0 (0) | |
| Diabetes | 8 (10·5) | 5 (25) | 3 (5·4) | 0·014 |
| Renal impairment | 3 (3·9) | 2 (10) | 1 (1·8) | 0·110 |
| Day of illness onset at presentation, days, median (range) | 5 (1–15) | 6 (1–14) | 4 (1–15) | 0·444 |
| Median (range) | Reference range | ||||
|---|---|---|---|---|---|
| Creatinine, µmol/l |
60–107 (Male) 50–90 (Female) |
70 (41–502) | 89 (70–502) | 71 (41–134) | |
| LDH, u/l | 250–580 | 401 (135–6374) | 403 (290–6374) | 398 (135–849) | |
| WBC, × 109/l | 6·92 (5·13–9·86) | 5·27 (2·60–18·55) | 6·11 (3·48–16·39) | 5·16 (2·6–18·55) | 0·1533 |
| Haemoglobin, g/l | 13·1–16·6 (Male) | 14·6 (8·7–16·8) | 15·05 (8·7–15·5) | 14·4 (0·98–16·8) | 0·1758 |
| 11·4–14·7 (Female) | |||||
| PLT#, × 109/l | 261 (201–364) | 205 (64–400) | 173·5 (64–299) | 221 (140–400) | 0·0003 |
| NEUT#, × 109/l | 3·90 (2·64–5·97) | 3·39 (1·10–15·05) | 4·56 (1·79–14·75) | 3·15 (0·98–16·76) | 0·0054 |
| LYMPH#, × 109/l | 2·22 (1·59–3·50) | 1·30 (0·43–3·88) | 1·015 (0·43–2·36) | 1·34 (0·54–3·88) | 0·0089 |
| MONO#, × 109/l | 0·55 (0·28–1·02) | 0·52 (0·17–1·36) | 0·48 (0·17–1·36) | 0·54 (0·19–1·35) | 0·3744 |
| EO#, × 109/l | 0·19 (0·05–1·10) | 0·04 (0–0·42) | 0·01 (0–0·24) | 0·05 (0–0·42) | 0·0019 |
| BASO#, × 109/l | 0·04 (0·01–0·11) | 0·02 (0–0·1) | 0·01 (0–0·10) | 0·02 (0–0·09) | 0·0056 |
| AS‐LYMPH#, × 109/l | 0·01 (0–0·03) | 0·01 (0–0·15) | 0·02 (0–0·15) | 0·01 (0–0·12) | 0·0329 |
| AS‐LYMPH%, % | 0·1 (0–0·39) | 0·30 (0–2·3) | 0·4 (0–1·6) | 0·2 (0–2·3) | 0·0949 |
| RE‐LYMPH#, × 109/l | 0·05 (0·01–0·18) | 0·04 (0–0·27) | 0·04 (0·01–0·27) | 0·04 (0–0·21) | 0·5195 |
| RE‐LYMPH%, % | 0·6 (0·2–2·4) | 0·8 (0·01–3·3) | 0·75 (0·1–2·30) | 0·8 (0–3·3) | 0·9427 |
| ‐AS‐LYMPH%/L, % | 0·41 (0–1·11) | 0·9 (0–24·6) | 2·15 (0–24·6) | 0·6 (0–8·1) | 0·0014 |
| ‐RE‐LYMPH%/L, % | 1·92 (0·54–6·77) | 3·35 (0·41–44·3) | 5 (0·8–44·3) | 2·85 (0–11·1) | 0·0352 |
#, absolute count; %, percentage of white cells; %/L, percentage of lymphocytes; AS‐LYMPH, antibody‐synthesising lymphocytes; BASO, basophils; EO, eosinophil; LDH, lactate dehydrogenase; LYMPH, lymphocytes; NEUT, neutrophil; PLT, platelets; RE‐LYMPH, reactive lymphocytes; WBC, white blood cell.
*
Comparison between severe/critical cases and mild cases.